CAMBRIDGE, Massachusetts, Oct. 16, 2017 (GLOBE NEWSWIRE) --
LogicBio Therapeutics, Inc., a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases, announced today that its company co-founder, Dr. Adi Barzel, will present new data from its genome-editing platform during the
25th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in two presentations this Wednesday in Berlin, Germany. The ESGCT will be held from October 17-20, 2017, at the
bcc Berlin.
 |
|
LogicBio co-founder Professor Adi Barzel, Ph.D, will present proof-of-concept efficacy data at the European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin |
|
 |
|
A preclinical-stage company founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Childrens Medical Research Institute in Sydney, LogicBio designed its approach to harness the natural power of homologous recombination enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases focusing first on inborn errors of metabolism, where there are few, if any, treatment options.
©LogicBio 2017 Illustration by OReilly Science Art LLC |
|
|
Dr. Barzel will present data in multiple animal models of disease demonstrating the extended therapeutic potential of LogicBios proprietary GeneRide platform technology. The GeneRide technology harnesses the natural power of homologous recombination to enable precise, site-specific
in vivo genome editing to deliver therapeutic genetic material without the use of vector-borne promoters or nucleases.
We are very excited to present proof-of-concept efficacy data in models of multiple genetic diseases and to demonstrate the breadth and the versatility of our GeneRide
TM technology, said LogicBio President and CEO Fred Chereau. We also feel fortunate developing our platform technology with world-renowned academic collaborators, enabling us to advance development candidates for early onset life-threatening diseases rapidly from the benchtop into the clinic.
Due to the genomic editing feature, LogicBios GeneRide
TM technology has shown in preclinical studies that it can provide stable therapeutic levels of life-saving proteins after a single injection. It overcomes a major challenge of the conventional gene therapy in pediatric indications dilution of therapeutic benefit due to the proliferation of cells in the growing tissue of a child. Thus, the GeneRide technology is uniquely suitable to treat many rare, early-onset and severe genetic diseases.
LogicBio presentations at the ESGCT Congress are as follows:
Oral Presentation
Title: GeneRide: Therapeutic in vivo gene targeting without nucleases
Session: Gene Editing I
When: October 18, 2017, 2:40 p.m. CEST
Room: C01
Poster Presentation
Title: GeneRide: Therapeutic in vivo gene targeting without nucleases
When: October 18, 2017, 6:50 p.m. CEST
Abstract Number: P129
A co-founder of LogicBio, Dr. Barzel is the president elect of the Israeli Society of Gene and Cell Therapy and a senior lecturer (associate professor) at the
Department of Biochemistry at Tel Aviv University. Dr. Barzel has a research background in homologous recombination and gene targeting. He is a Summa cum Laude graduate of the Adi Lautman interdisciplinary program for outstanding students, and has earned his PhD in genetics from the laboratory of Professor Martin Kupiec at Tel Aviv University. Previously, Major Adi Barzel was a company commander in an armor brigade and in the officers academy of the Israeli Defense Forces. He invented the GeneRide technology during his time as a postdoctoral fellow at the
Kay Lab at Stanford Medicine, Stanford University. He has co-authored scientific papers in high-impact journals describing the GeneRide technology and its applications.
About LogicBio Therapeutics (www.logicbio.com; twitter: @logicbio)
A preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Childrens Medical Research Institute in Sydney the companys core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination enabling precise, site-specific transfer of the genetic material without the use of vector-borne promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the companys discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.
Attachments:
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/21431f6d-93d7-4c5f-a5d1-1a51641c6b2f
Attachments:
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/81511cac-ee28-4f0e-add0-dcceb0ea0a5c
Attachments:
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/95980a56-cec5-4e55-850b-a5f2a1713159 
Caroline Grossman
LogicBio Therapeutics, Inc.
(781) 771.5579
caroline@mirepoixllc.com
